Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solithromycin vs Moxifloxacin in CABP
NCT01968733Phase 3Completed
- Sponsor
- Melinta Therapeutics
- Start
- Nov 2013
- Primary completion
- Jul 2015
- Modality
- RNA-Targeting Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of solithromycin in community-acquired bacterial pneumonia (CAP), sponsored by Melinta Therapeutics. Started Nov 2013; status: completed.
02
Drugs
solithromycin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT01968733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01968733.